Skip to main content

Treatment Clinical Trials for Soft Tissue Sarcoma

Review the soft tissue sarcoma treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 76-100 of 122

Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients with Soft Tissue Sarcoma, Bone Sarcoma, or Colorectal Cancer Metastatic to the Lungs
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
PEEL-224 Alone and in Combination with Vincristine and Temozolomide for the Treatment of Refractory, Progressive, or Relapsed Childhood Solid Tumors, Neuroblastoma or Rhabdomyosarcoma
Status: Active
Location: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Abemaciclib for the Treatment of Patients with HIV-Associated and HIV-Negative Kaposi Sarcoma
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
NHS-IL12 Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Retifanlimab with or without Gemcitabine and Docetaxel in Patients with Advanced, Unresectable or Metastatic Soft Tissue Sarcoma
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Modified Donor Peripheral Blood Stem Cells in Combination with Zoledronic Acid for the Treatment of Pediatric, Adolescent, and Young Adult Patients with Relapsed or Refractory Solid Tumors
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida
Single Protein Encapsulated Doxorubicin for the Treatment of Advanced, Refractory or Relapsed Solid Tumor Malignancies
Status: Active
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
Tivozanib and Atezolizumab for the Treatment of Advanced, Unresectable, or Metastatic Immunologically Cold Tumor Types
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida
Evaluation of Abemaciclib and Radiation Therapy Before Surgery for the Treatment of High-Risk Adipocytic Retroperitoneal Sarcoma
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
CBT-1® in Combination With Doxorubicin in Patients With Metastatic, Unresectable Sarcomas Who Previously Progressed on Doxorubicin
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Zanzalintinib in Combination with Ipilimumab and Nivolumab for the Treatment of Metastatic or Unresectable Refractory Soft Tissue Sarcoma
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Hypofractionated Radiation and Lymphodepleting Chemotherapy Followed by B7-H3-CAR T Cells for the Treatment of Pediatric Patients with Relapsed or Refractory Sarcomas
Status: Active
Location: Saint Jude Children's Research Hospital, Memphis, Tennessee
Fampridine in Combination with Imatinib Mesylate before Surgery for the Treatment of KIT Exon 11 Mutant Gastrointestinal Stromal Tumor (GIST)
Status: Active
Location: UC San Diego Moores Cancer Center, La Jolla, California
FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Targeted IL12 T-cell Therapy for Treatment Advanced or Metastatic Soft Tissue or Bone Sarcomas
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Genetically Engineered Cells (NY-ESO-1 TCR/IL-15 NK cells) for the Treatment of Patients with Relapsed or Refractory Synovial Sarcoma, Myxoid Liposarcoma, or Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
RNA-Lipid Particle Vaccine for the Treatment of Early Melanoma Recurrence after Anti-PD-1 Antibody Therapy or Uresectable or Metastatic Soft Tissue Sarcoma
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida
Palbociclib with Pembrolizumab for the Treatment of Patients with Locally Advanced, Metastatic or Unresectable Sarcomas
Status: Active
Location: University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa
Tumor Infiltrating Lymphocytes for the Treatment of Children with High Risk Solid Tumors
Status: Active
Location: Johns Hopkins All Children's Hospital, Saint Petersburg, Florida
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas